gdc
FDA Approvals, News & UpdatesCervical Cancer

Tivdak First Antibody–Drug Conjugate FDA Approved for Recurrent or Metastatic Cervical Cancer

In September, the FDA approved Tivdak (tisotumab vedotin) for the treatment of women with recurrent or metastatic cervical cancer that progressed during or after chemotherapy. This is the first tissue factor–directed antibody and microtubule inhibitor conjugate approved for women with advanced cervical cancer.
October 2021 Vol 7 No 5

On September 20, 2021, the FDA accelerated the approval of Tivdak (tisotumab vedotin-tftv; from Seagen and Genmab), a tissue factor–directed antibody and microtubule inhibitor conjugate administered as an intravenous infusion, for the treatment of women with recurrent (coming back) or metastatic (spreading) cervical cancer that progressed during or after receiving chemotherapy.

This is the first drug of this type that is approved for women with advanced cervical cancer, offering patients a much-needed new treatment option.

“Tivdak’s approval as a monotherapy in the U.S. is an important milestone for women with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy, as they are in need of a new treatment option,” said Jan van de Winkel, PhD, Chief Executive Officer of Genmab.

The FDA approved Tivdak based on results from an open-label, multicenter, single-arm clinical trial that included 101 patients with recurrent or metastatic cervical cancer who had received up to 2 regimens of systemic therapies that included at least 1 platinum-based chemotherapy regimen for recurrent or metastatic cervical cancer.

All the patients in this study received intravenous infusion of Tivdak every 3 weeks until their cancer progressed or they had unacceptable side effects.

The response rate to Tivdak therapy was 24%, meaning that almost a quarter of the patients had a response to this new treatment, and the average length of response was 8.3 months.

The most common side effects with Tivdak included reductions in some blood chemistry levels, fatigue, nausea, peripheral neuropathy, hair loss, bleeding (including nose bleeding), dry eye, diarrhea, and rash.

The prescribing information for Tivdak includes a warning to doctors about the potential for serious ocular side effects.

Share this:

Recommended For You
FDA Approvals, News & UpdatesLymphoma
Brukinsa Approved for Marginal-Zone Lymphoma and for Waldenström’s Macroglobulinemia
In September 2021, the FDA approved Brukinsa oral capsules for adults with relapsed or refractory marginal-zone lymphoma. And in August, the FDA approved Brukinsa for adults with Waldenström’s macroglobulinemia, a rare, slow-growing type of non-Hodgkin lymphoma.
Cervical Cancer
For Women with Locally Advanced Cervical Cancer, Adjuvant Chemotherapy Not Recommended After Chemoradiation
By Meg Barbor, MPH
This article explains why for women with advanced cervical cancer, using adjuvant chemotherapy has no benefit, and possible severe side effects.
Last modified: November 8, 2021

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest